THE EFFECT OF AQUEOUS STEM BARK EXTRACT OF ERYTHRINAMILDBRAEDII ON CARBON TETRACHLORIDE INDUCED LIVER DAMAGE IN RATS

* Wudil, A.M and Sarki, S. I.
Department of Biochemistry, Bayero University, Kano- Nigeria.
*Correspondence author: amwudil@hotmail.com.

ABSTRACT
This study evaluated the curative effects of aqueous stem bark extract of Erythrina mildbraedii in CCL₄ induced liver damage. With the exception of group 1 (positive control), CCL₄ was administered at a dose of 150 mg/kg to groups II, III, IV and V. Administration of CCL₄ caused profound hepatic damage as indicated by elevation in serum levels of liver transaminases, alkaline phosphatase, total and direct bilirubin. There was depletion of serum proteins and albumin. Administration of aqueous stem bark extract of Erythrina mildbraedii at daily oral doses of 50, 100, 150mg/kg reversed these biochemical aberrations to a significant level. The curative effects of stem bark extracts of Erythrina mildbraedii were further substantiated by histopathological examination of the liver hepatocytes. The result of the study suggested that aqueous stem bark extract of Erythrina mildbraedii posses hepatocurative effects.

Keywords: Carbontetrachloride, Erythrina mildbraedii, liver enzymes, hepatotoxicity.

INTRODUCTION
Liver is exposed to many potentially toxic substances via gastrointestinal tract from the diet, food additives, contaminants and drugs and is frequently a target in experimental animals. By virtue of its position, structure, function and biochemistry, the liver is especially vulnerable to damage from toxic compounds (Timbrell, 2009). As the major drug metabolizing and detoxifying organ in the body, the liver is subjected to potential damage from an array of pharmaceutical and environmental chemicals. Injury may result from direct toxicity via hepatic conversion of a xenobiotic to an active toxin or through immune mechanisms, usually by a drug or a metabolite acting as hapten to convert a cellular protein into an immunogen (Kumar et al., 2006). Medicinal plants are those plants that provide medicines to prevent disease, maintain health or cure sickness. In other word, these plants benefit virtually everyone on the earth. Plants provide the predominant ingredients of medicines in most traditional systems of healing and have been the source of inspiration for several new drug researches to major pharmaceutical companies (Maiti et al., 1999). The plants that posses therapeutic properties or exact beneficial pharmacological effects on the body are generally designated as “medicinal”. Medicinal plants are of great importance to the health of individuals and communities. The medicinal value of these plants lies in some chemical substances that produce a definite physiological action on the human body. The most important of these bioactive constituents of plants are alkaloids, tannins, flavonoids, and phenolic compounds (Hill, 1993). They play a significant role in providing primary health care services to rural people. They serve as therapeutic agents as well as important raw materials for the manufacture of traditional and modern medicines. Erythrina mildbraedii (Minjirya in hausa) is a tree that grow up to 30 m in height and is native to West Africa. Erythrina species produce many secondary metabolites, some of which have a function of defence systems against pathogenic fungi and bacteria (Karthikeyan et al., 2010). Ethnobotanical discovery process of sub-Saharan Erythrina has resulted in promising biological activities (Kone et al., 2004; Nguyen et al., 2010). Many Erythrina species showed real potential for fighting pathogenic agents associated with public health problems in sub-Saharan Africa. For e.g. multidrug resistant pathogens are responsible for therapeutic failures (Kone and Kamanzi, 2009). This situation is serious because microbial infections are most frequent opportunistic diseases occurring during HIV/AIDS which affected many people in Africa. Moreover, during this infection, cancer and cardiovascular diseases, oxidative stress and generating free radicals is known to cause damage to cell and immune system of patients. Scientists are searching for new molecules that could provide alternative to conventional treatments (Coulidiati et al., 2011).

High incidence of cancer, inflammation, and cardiovascular diseases are attributed to oxidative stress. Some Sub-Saharan Erythrina species are used by traditional practitioners to treat cancer and inflammation. These plants were investigated for cancer chemo protective agents and inhibitors of enzyme borne diseases.
The stem bark of the plant collected was carefully washed in clean water, and then dried at room temperature. They were pulverized to coarse powder and distilled water (500 cm$^3$) was added to 100g of the powdered stem bark in a conical flask. The content of the flask was then shaken and the top was covered with aluminium foil and kept for 48 hours. The extract was then obtained by filtration using whatman No 1filter paper. The filtrate was dried and then reconstituted for administration.

**Experimental Animals**

Twenty four (24) white albino rats (weighing 160 to250g) were purchased from the Animal Room of the Biological Sciences Department, Bayero University,Kano. The rats were maintained under standard laboratory conditions and were allowed free access to both food and water throughout the period of the experiment. The volume (cm$^3$) of the stem bark aqueous extract given to each rat was determined by its weight and required dose as follows:

$$
\text{Volume administered (cm}^3\text{)} = \frac{\text{weight of rat (kg)} \times \text{Required dose (mg/kg)}}{\text{Concentration of the extract (mg/ cm}^3\text{)}}
$$

**Experimental Design**

Twenty four (24) experimental rats were divided into eight groups of three (3) rats each. Liver toxicity was induced in groups I – VIII using CCl$_4$ according to Alhassan et al., (2009).

- **Group I:** normal rats (No extract, no CCl$_4$ administered)
- **Group II:** CCl$_4$ administered no extract (Test Control)
- **Group III:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 50 mg/kg orally. Once daily for two weeks).
- **Group IV:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 100 mg/kg orally. Once daily for two weeks).
- **Group V:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 50mg/kg orally, once daily for two weeks).
- **Group VI:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 100mg/kg orally, once daily for four weeks).
- **Group VII:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 150mg/kg orally, once daily for four weeks).
- **Group VIII:** were administered with aqueous stem bark extract of *Erythrina mildbraedii* (Dose; 150mg/kg orally, once daily for four weeks).

**MATERIALS AND METHODS**

**Plant identification and Collection**

*Erythrina mildbraedii* stem bark was collected from Song local Government Area of Adamawa State. It was identified and authenticated by a Botanist at the Botany unit of the Faculty of Science, Bayero University Kano, Nigeria

**Extraction of Plant Materials**

The stem bark of the plant collected was carefully washed in clean water, and then dried at room temperature. They were pulverized to coarse powder and distilled water (500 cm$^3$) was added to 100g of the powdered stem bark in a conical flask. The content of the flask was then shaken and the top was covered with aluminium foil and kept for 48 hours. The extract was then obtained by filtration using whatman No 1filter paper. The filtrate was dried and then reconstituted for administration.
Blood and Tissue Samples Collection
Rats in groups I and II were sacrificed after 48hrs of CCl₄ administration to confirm lipid peroxidation and liver damage. Groups III- V were sacrificed after two weeks of extract administration, while groups VI- VIII were sacrificed after 4 weeks of extract administration. The liver from both control and test animals were excised, sliced and fixed in 10% formaldehyde solution and used for histological examination.

Biochemical Analysis
Blood samples were collected, allowed to clot and centrifuged at 2000 rpm for 10min to obtain the serum samples. For each serum sample, the level of alanine aminotransferase(ALT), aspartate amino transferase (AST) were determine using the method of Reitman and Frankel (1957), alkaline phosphatase (ALP) using the method of Rec (1972), direct bilirubin(DB) and total bilirubin (TB) by the method of Jendrassik and Grof (1938), total protein(TP) using the method of Tietz (1995) and albumin (ALB) using the method of Grant (1987) were analyzed in order to assess liver function.

Histopathology
Histological examinations were conducted using the method of Auwioro (2010). The liver tissues were fixed in multiple baths of ethanol, embedded in paraffin, sectioned and stained with hematoxylin and eosin.

Statistical Analysis
The data was statistically analysed using one-way analysis of variance (ANOVA) with P value < 0.01 considered to be significant. Graphpad Instat 3 software (2000). Version 3.05, Graphpad Inc was used for all the analysis.

RESULTS
The hepatocurative activity of aqueous stem bark extract of Erythrina mildbraedii was evaluated in the experimental animals two weeks and four weeks after inducement of liver damage. Table 1 shows the mean serum level of liver indices (AST, ALT, ALP, DB, TB and TP), for group of rats 48 hours after administration of 150mg/Kg CCl₄ (Group II) and compared to that of normal control Group I which is to confirm inducement of hepatotoxicity and lipid peroxidation by the CCl₄.

The result obtained showed a significant increase (P<0.01) in the mean serum level of AST,ALT, ALP, DB and TB while that of TP and ALB decreases in the test control group when compared with the normal control rats.

After two weeks of oral administration of aqueous stem bark extract of Erythrina mildbraedii at a daily dose of 50mg/kg only the mean serum level of ALP significantly decreased (P<0.01) even though the level of AST, ALT, DB decreased while that of ALB and TP increased but showed no significant difference (P<0.01) when compared with test control groups. However the groups administered with a daily dose of 100 and 150mg/kg had their mean serum levels of AST, ALT, ALP, DB and TB decreases significantly (P<0.01) when compared to test control rats but still higher than that of the normal control rats while that of ALB significantly increased (P<0.01) when compared with test control rats but lower than that of the normal control groups. The decrease in the mean serum levels of AST, ALT, ALP, DB, and TB and increase in the level of ALB was found to be dose dependent.

After four weeks of oral administration of aqueous stem bark extract of Erythrina mildbraedii the mean serum level of AST,ALT,ALP,DB and TB significantly decreased (P<0.01) when compared with test control groups while that of ALB and TP increased significantly (P<0.01) when compared to test control groups (Table 2). The mean serum level returned to near normal irrespective of the dose administered.

Plate 1 of the histopathology result showed section of liver of normal rats with hepatocytes arranged in cord radiating from central venules. Plate 2 showed area of the liver with necrosis, fibrosis and degeneration of hepatocytes due to damage caused by CCl₄ administration. Plate 3 showed section of the liver area with fibrosis after administration of 50mg/kg of the extract for two weeks. Plates 4 and 5 showed cross section of the liver with fat cells after administration of 100mg/kg and 150mg/kg of the extract for two weeks. Plates 6, 7 and 8 showed no significant pathology, they showed hepatocytes arranged in cord radiating from central venules after administration of varying doses of the extract for four weeks.
Table 1: Effects of oral administration of aqueous stem bark extract *Erythrina mildbraedii*(ASBEEM) on serum biochemical indices of CCl₄-induced hepatotoxicity in rats after two weeks.

<table>
<thead>
<tr>
<th>Groups/Dose(mg/kg)</th>
<th>AST(U/L)</th>
<th>ALT(U/L)</th>
<th>ALP(U/L)</th>
<th>TP(g/L)</th>
<th>ALB(g/L)</th>
<th>DB(Umol/L)</th>
<th>TB(Umol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (Normal rats)</td>
<td>23.33±1.53</td>
<td>12.00±1.00</td>
<td>110.33±1.53</td>
<td>67.33±2.08</td>
<td>43.33±5.51</td>
<td>7.70±1.15</td>
<td>18.33±0.75</td>
</tr>
<tr>
<td>II CCl₄(150mg/kg)</td>
<td>60.00±2.65*</td>
<td>44.00±6.25*</td>
<td>273.67±4.93*</td>
<td>37.33±3.51*</td>
<td>25.33±5.51*</td>
<td>20.40±0.78*</td>
<td>37.10±2.44*</td>
</tr>
<tr>
<td>III ASBEEM(50mg/kg)</td>
<td>44.67±4.04</td>
<td>29.00±6.00</td>
<td>245.00±3.61^c</td>
<td>43.67±6.66</td>
<td>33.67±2.31</td>
<td>12.87±0.85</td>
<td>27.87±1.57</td>
</tr>
<tr>
<td>IV ASBEEM(100mg/kg)</td>
<td>41.00±1.00^a</td>
<td>24.67±1.53^b</td>
<td>191.67±12.74^c</td>
<td>51.33±2.08</td>
<td>38.00±1.73^c</td>
<td>10.87±1.16^l</td>
<td>25.50±0.89^p</td>
</tr>
<tr>
<td>V ASBEEM(150mg/kg)</td>
<td>32.00±2.00^a</td>
<td>19.00±1.00^b</td>
<td>177.00±1.00^c</td>
<td>52.00±4.36</td>
<td>37.33±2.08^c</td>
<td>11.60±0.98^f</td>
<td>21.07±2.01^g</td>
</tr>
</tbody>
</table>

Results are expressed as mean±SD for three determinations, n=3

Values with asterisk are significantly different at P<0.01 when compared with normal rats.

Values in the same column bearing similar superscript are significantly different at P<0.01 when compared with the test control groups

Table 2: Effects of oral administration ASBEEM on serum biochemical indices of CCl₄-induced hepatotoxicity in rats after four weeks.

<table>
<thead>
<tr>
<th>Groups/Dose(mg/kg)</th>
<th>AST(U/L)</th>
<th>ALT(U/L)</th>
<th>ALP(U/L)</th>
<th>TP(g/L)</th>
<th>ALB(g/L)</th>
<th>DB(Umol/L)</th>
<th>TB(Umol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (Normal rats)</td>
<td>23.33±1.53</td>
<td>12.00±1.00</td>
<td>110.33±1.53</td>
<td>67.33±2.08</td>
<td>43.33±5.51</td>
<td>7.70±1.15</td>
<td>18.33±0.75</td>
</tr>
<tr>
<td>II CCl₄(150mg/kg)</td>
<td>60.00±2.65*</td>
<td>44.00±6.25*</td>
<td>273.67±4.93*</td>
<td>37.33±3.51*</td>
<td>25.33±5.51*</td>
<td>20.40±0.78*</td>
<td>37.10±2.44*</td>
</tr>
<tr>
<td>III ASBEEM(50mg/kg)</td>
<td>23.67±4.04</td>
<td>14.00±2.00</td>
<td>123.00±11.79</td>
<td>50.33±2.52</td>
<td>38.00±1.00</td>
<td>9.77±0.57</td>
<td>21.47±2.08</td>
</tr>
<tr>
<td>IV ASBEEM(100mg/kg)</td>
<td>25.67±3.01^h</td>
<td>13.80±0.72^i</td>
<td>117.00±4.36^j</td>
<td>59.33±2.30^k</td>
<td>40.67±2.52</td>
<td>9.90±1.35^m</td>
<td>22.60±1.90^n</td>
</tr>
<tr>
<td>V ASBEEM(150mg/kg)</td>
<td>26.00±1.00^h</td>
<td>12.27±0.58^i</td>
<td>113.67±7.76^j</td>
<td>66.33±3.79^k</td>
<td>41.00±8.00</td>
<td>9.53±2.55^m</td>
<td>22.17±2.82^n</td>
</tr>
</tbody>
</table>

Results are expressed as mean±SD for three determinations, n=3

Values with asterisk are significantly different at P<0.01 when compared with normal rats.

Values in the same column bearing similar superscript are significantly different at P<0.01 when compared with test control groups
Plate 1 shows photomicrograph of cross section of liver of normal rats. Plate 2 showed the section of the liver administered with 150mg/kg body weight of CCl₄. Plates 3, 4 and 5 showed cross section of the liver administered with varying doses of ASBEEM for two weeks. Plates 6, 7 and 8 showed cross section of the liver treated with varying doses of ASBEEM for four weeks.
Plate 5: Section of the liver area of fat cells after ASBEEM 150mg/kg administered for two weeks. H & E STAIN X 10

Plate 6: Section of the liver shows no significant pathology, they showed hepatocytes arranged in cord radiating from central venules after ASBEEM 50mg/kg administered for four weeks. H & E STAIN X 10

Plate 7: Section of the liver shows no significant pathology, they showed hepatocytes arranged in cord radiating from central venules after ASBEEM 100mg/kg administered for four weeks. H & E STAIN X 10

Plate 8: Section of the liver shows no significant pathology, they showed hepatocytes arranged in cord radiating from central venules after ASBEEM 150mg/kg administered for four weeks. H & E STAIN X 10
DISCUSSION
Liver injury induced by CCl₄ is the best-characterized system of xenobiotic-induced hepatotoxicity and is a commonly used model for the screening of medicinal and toxicological activities of drugs (Brautbar and Williams, 2002; Brent and Rumack, 1993). Information in Table 1 showed that CCl₄ administration caused significant elevation of ALT, AST, ALP, direct bilirubin and total bilirubin by (CYP2E1). This highly reactive free radical readily reacts with molecular oxygen to form the trichloromethyl peroxy radical (CCl₃O·). Both trichloro and peroxyl radicals can bind to cellular proteins and lipids, initiating lipid peroxidation and liver damage. Direct and total bilirubin levels were elevated in CCl₄-treated rats, caused either due to an increased production, decreased secretion from the liver or blockage of the bile ducts (Bun et al., 2006). Bilirubin is derived from the regular degradation of haemoglobin from the red blood cells and excreted from the liver in the bile. It is a chemical normally present in the blood in small amounts and used by the liver to produce bile. When the liver cells are damaged, they may not be able to excrete bilirubin in the normal way, causing a build-up of bilirubin in the blood and extracellular fluid (Saukonen et al., 2006).

Liver is an important site for the synthesis of many serum proteins and the levels of serum proteins are decreased in hepatic diseases. The oxidative damage of some amino acids is considered as the major cause of metabolic dysfunction in hepatic damage (Bandyopadhyay et al., 1999). Serum albumin is the main plasma protein produced in the liver, a clinically useful indicator of hepatic synthetic function (Sturgill and Lambert 1997).

Liver injury is associated with a decline in the concentration of serum albumin, and hypoalbuminemia has been considered to be a consequence of a decreased rate of hepatic synthesis of the essential protein in both humans and animals (Ruo et al., 2002). Accordingly, the serum albumin and total protein levels were determined in the present study. The CCl₄-treated rats exhibited significantly lower serum total protein and albumin levels compared with the normal control rats. However, administration of ASBEEM increased these serum levels to a normal control range. This suggests that ASBEEM possesses ability to promote protein synthesis that plays a significant contributory role in hepatoprotective activity, which in turn has been shown to enhance proliferative process and the production of hepatocytes (Awang, 1993).

REFERENCES
Bajopas Volume 8 Number 1June, 2015


Kone, W. M., Atindehou, K. K., Terreaux, C., Hostettmann, K., Traore, D., and Dosso, M. (2004). Traditional Medicine in North Cote-

D’ivoire: Screening of 50 Medicinal Plants for Antibacterial Activity. J. Ethnopharmacol. 93:43-49.


